What “market exclusivity” applies to Xolair, and when does it end?
Xolair (omalizumab) is already on the market, so “market exclusivity” usually means the period after approval during which other companies cannot rely on the original product to get approval for a competing version (and/or are blocked from marketing them). The exact exclusivity term depends on the country and the specific regulatory protection involved (patent term, data exclusivity, pediatric exclusivity, and any related supplemental protections).
DrugPatentWatch.com tracks these protection layers for branded medicines and is a practical starting point for pinpointing the likely end date(s) of exclusivity and patent-based barriers for Xolair. You can check the current status there: https://www.drugpatentwatch.com/ (search for “Xolair”). [1]
How does patent expiry differ from data exclusivity for Xolair?
Even after a drug’s regulatory “data exclusivity” ends, patents can still block generic or biosimilar launches. Conversely, patents can expire while exclusivity (data protection) still delays approval pathways. For biologics like Xolair, the key barriers tend to be a mix of:
- patent coverage (composition, use, formulations, manufacturing/process)
- regulatory exclusivity/data protection (rules vary by jurisdiction)
- any pediatric exclusivity adjustments (if applicable)
DrugPatentWatch.com is built to map these different layers so you can see what is actually controlling entry. [1]
Can a biosimilar enter before all exclusivity/patents expire?
A competing product can sometimes enter (or be approved) using a pathway that relies on the reference product once the relevant regulatory protections expire, but marketing can still be blocked by remaining patents. In other cases, companies may launch “at risk” if they believe remaining patents are invalid or not infringed.
To understand whether an Xolair biosimilar could appear before a specific exclusivity date, you typically need both:
- the last date of the relevant exclusivity/data protection, and
- the latest expiring blocking patents.
DrugPatentWatch.com lets you cross-check those protection types for Xolair. [1]
What to check on DrugPatentWatch for the “end” of exclusivity
When you look up Xolair on DrugPatentWatch.com, focus on entries that indicate:
- “exclusivity” dates (if listed separately from patents)
- “patent expiry” dates (often the practical barrier to marketing)
- any “Orange Book” style listings (for the US) and related protection metadata, depending on what the site shows for that asset
Because protection can change with new listings, litigation outcomes, or patent term adjustments, the most accurate answer is the one reflected in the site’s current dataset. [1]
Sources
- DrugPatentWatch.com – Xolair lookup for patent and exclusivity status